Masroor Mirza, Prasant Yadav, Kajal Tanwer, R C M Kaza, S K Jain, Nita Khurana, P C Ray and Alpana Saxena
Maulana Azad Medical College and Associated Hospitals, India
Posters & Accepted Abstracts: Gynecol Obstet
miRNA-21 is recognized as the main active candidate and has high expression in many solid tumors consequential cell proliferation, differentiation, apoptosis and closely related to metastasis of disease. Study aimed to evaluate the serum miRNA-21 expression and therapy outcome in breast cancer patients and cell lines. 75 histopathologically confirmed newly diagnosed breast cancer patients were included in the study, before and after therapy patient�s blood sample were collected and analysed serum microRNA-21 expression by quantitative real time PCR. In patients, 8.9 mean fold increased microRNA-21 expression was observed compare to controls. Increased expression was found to be associated with advanced stage (11.72 fold), lymph node involvement (11.12 fold) and distant metastases (20.17 fold). After treatment, significant decrease in miRNA-21 expression was observed and found to be significant (p<0.0001). Patients treated with neoadjuvant therapy had significant impact on miRNA-21 suppression and found to be significantly associated with different clinicopathological features of patients. Increased miRNA-21 expression was also found to be significantly associated with poor survival of breast cancer patients (p=0.002). microRNA-21 expression could be used as promising predictive indicators for breast cancer prognosis. microRNA-21 over-expression was associated with response to neoadjuvant therapy may perhaps be consider as primary treatment choice.
Email: mirzamasroor1986@gmail.com
